Slc6A4 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Serotonin Transporter (SERT) |
|---|
| Gene Symbol | SLC6A4 |
| UniProt ID | P31645 |
| PDB ID | 5I6X, 6DZZ, 6V02 |
| Molecular Weight | 63 kDa (glycosylated) |
| Subcellular Localization | Plasma membrane, presynaptic terminal |
| Protein Family | SLC6 family (Na+/Cl- dependent neurotransmitter transporters) |
The Serotonin Transporter (SERT) is a membrane protein that reuptakes serotonin (5-HT) from the synaptic cleft back into the presynaptic neuron, terminating serotonin signaling[1]. Encoded by the SLC6A4 gene, SERT is the target of widely used antidepressant medications including selective serotonin reuptake inhibitors (SSRIs). SERT plays critical roles in mood regulation, sleep, appetite, and cognitive function, making it a key protein in both normal neurophysiology and neuropsychiatric disorders.
¶ Domain Architecture
SERT is a member of the SLC6 family with 12 transmembrane domains:
- N-terminus: Intracellular, contains phosphorylation sites
- Transmembrane domains 1-12: Alpha-helical membrane segments
- Extracellular loops: glycosylation sites, disulfide bonds
- C-terminus: Intracellular, contains PDZ-binding motif
Recent cryo-EM structures have revealed the transport mechanism[2]:
- Outward-facing conformation: Substrate binding site open to extracellular space
- Inward-facing conformation: Substrate binding site open to cytoplasm
- Leucine transporter (LeuT) homology: Bacterial homolog providing structural insights
- N-glycosylation: Asn-glycosylation in extracellular loops
- Phosphorylation: Serine/threonine phosphorylation regulates activity
- Palmitoylation: Membrane anchoring
SERT uses a symport mechanism coupling serotonin transport to Na+ and Cl- gradients[3]:
- Binding: Serotonin binds to outward-facing SERT
- Na+ binding: Two Na+ ions bind cooperatively
- Cl- binding: One Cl- ion co-transports
- Conformational change: Transporter shifts to inward-facing state
- Release: Serotonin and ions released into cytoplasm
- Recycling: Transporter returns to outward-facing state
| Substrate |
Affinity |
Notes |
| Serotonin (5-HT) |
High |
Primary substrate |
| Dopamine |
Low |
Minor substrate |
| Tryptamine |
Moderate |
Endogenous substrate |
| MDMA |
High |
Substrate, releaser |
- Phosphorylation: PKC activation reduces activity
- Substrate trafficking: Acute regulation via endocytosis
- Transcriptional control: Long-term regulation via gene expression
SERT is expressed in serotonin-producing neurons:
- Raphe nuclei: Dorsal and median raphe (primary site)
- Cortex: Moderate expression in prefrontal, temporal regions
- Hippocampus: Dentate gyrus, CA regions
- Amygdala: Moderate expression
- Basal ganglia: Low expression
- Plasma membrane: Primary location on presynaptic terminals
- Synaptic vesicles: Vesicular SERT for reuptake
- Dendrites: Dendritic SERT for autoreceptor function
- Non-neuronal: Platelets, intestinal enterochromaffin cells
SERT alterations in AD[4]:
- Serotonergic deficits: Reduced SERT binding in AD cortex
- Depression comorbidity: High depression in AD patients linked to SERT
- Amyloid interactions: Aβ may affect SERT function
- Therapeutic implications: SSRIs may have disease-modifying effects
- Depression in PD: SERT polymorphisms affect PD depression risk
- SSRI use: May affect L-DOPA efficacy
- Serotonergic neurons: PD affects raphe nuclei
- Major depressive disorder: SSRIs target SERT
- Anxiety disorders: SERT function altered
- Autism: SERT polymorphisms associated
- OCD: SERT as therapeutic target
| Drug |
Approval |
Notes |
| Fluoxetine (Prozac) |
1987 |
First SSRI |
| Sertraline (Zoloft) |
1991 |
Highly selective |
| Paroxetine (Paxil) |
1992 |
Short half-life |
| Escitalopram (Lexapro) |
2002 |
Most selective |
| Citalopram (Celexa) |
1998 |
Racemic mixture |
- Serotonin-norepinephrine reuptake inhibitors (SNRIs): Venlafaxine, duloxetine
- Tricyclic antidepressants (TCAs): Imipramine, amitriptyline
- Monoamine oxidase inhibitors (MAOIs): Indirect SERT effects
- Gastrointestinal: Nausea, diarrhea
- Sexual dysfunction: Anorgasmia, decreased libido
- CNS: Insomnia, agitation, headache
- Serotonin syndrome: With combinations
- SERT knockout mice: Anxiety-related behaviors
- Transgenics: Overexpression and mutant models
- Conditional knockouts: Brain-specific deletion
- Structural biology: Cryo-EM structures of human SERT
- Polymorphisms: 5-HTTLPR and disease risk
- Biomarkers: SERT imaging in disease
- Novel therapeutics: Allosteric modulators
The study of Slc6A4 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Rudnick G (2006). Serotonin transporters: Structure and function. Journal of Membrane Biology. 213(2):101-110.
[2] Coleman JA, et al. (2019). Crystal structures of the human serotonin transporter in complex with SSRIs. Nature. 572(7768):55-60.
[3] Kristensen AS, et al. (2011). SLC6 neurotransmitter transporters: Structure, mechanism, and drug discovery. Pharmacology & Therapeutics. 130(1):71-88.
[4] Meltzer CC, et al. (1998). Serotonin in aging, depression, and Alzheimer's disease. Journal of Geriatric Psychiatry and Neurology. 11(2):67-73.